Bluejay Investor Presentation Deck

Symphony™M IL-6 Potential Clinical Advantages v. Current Tests Used for Sepsis Patients IL-6 negative predictive value (NPV) superior to other standard biomarkers Interleukin-6 (IL-6) 0.801 Metric Area Under Receiver Operator Characteristic Curve (AUC) ●●● Youden Index Cutoff Sensitivity Specificity NPV 1.52 DIAGNOSTICS 35 pg/mL 0.89 (0.65, 0.99) 0.64 (0.55, 0.72) 0.98 (0.92, 1.00) C-Reactive Protein (CRP) 0.578 1.35 113.95 mg/mL 0.44 (0.22, 0.69) 0.91 (0.84, 0.95) 0.92 (0.86, 0.96) Lactate 0.680 1.29 1.75 mmol/L 0.56 (0.31, 0.78) 0.74 (0.61, 0.84) 0.85 (0.72, 0.93) Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Sensitivity 1.0 0.8- 0.6- 0.4- 0.2- 0.0 1.0 ROC Curves of Biomarker Prediction of IMV 0.8 0.6 IL-6 (AUC = 0.801) CRP (AUC = 0.578) Lactate (AUC = 0.680) 0.4 Specificity Bluejay clinical study assessed ability of Symphony IL-6 to predict risk for invasive mechanical ventilation (IMV) in COVID-19 patients at time of hospital admission Favorable clinical performance demonstrated 89% sensitivity, 64% specificity and 98% NPV, which highlights potential higher clinical utility of IL-6 compared to other standard biomarkers to identify patients at future risk of IMV. IMV is associated with respiratory failure, which is common in sepsis patients. 0.2 0.0 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | November 2023 9

View entire presentation